Osimertinib for terminal non-small-cell lung cancer - GIM Journal Watch

KRAS G12C mutation in NSCLC. iStock.com/Nemes Laszlo

By Dr Druin Burch

Pamrevlumab for idiopathic pulmonary fibrosis, osimertinib for terminal non-small-cell lung cancer and beta blockers to prevent COPD exacerbations are among this month’s roundup of the essential general internal medicine papers from the major medical journals.

The Lancet